Aptose Biosciences Inc. (NASDAQ:APTO)‘s stock had its “buy” rating reaffirmed by equities research analysts at Roth Capital in a research report issued on Friday. They presently have a $8.00 price objective on the stock. Roth Capital’s price target suggests a potential upside of 233.33% from the stock’s previous close.

A number of other equities research analysts have also issued reports on the stock. Canaccord Genuity reissued a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Saturday. Zacks Investment Research raised shares of Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th. RBC Capital Markets reissued an “outperform” rating on shares of Aptose Biosciences in a research note on Tuesday, September 13th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $23.00 target price on shares of Aptose Biosciences in a research note on Saturday, June 25th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $12.30.

Analyst Recommendations for Aptose Biosciences (NASDAQ:APTO)

Shares of Aptose Biosciences (NASDAQ:APTO) opened at 2.40 on Friday. Aptose Biosciences has a 52 week low of $1.92 and a 52 week high of $6.40. The firm’s market capitalization is $30.94 million. The stock’s 50 day moving average price is $2.22 and its 200 day moving average price is $2.47.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/aptose-biosciences-inc-apto-receives-buy-rating-from-roth-capital.html

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bank of Montreal Can acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned about 0.43% of Aptose Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 19.47% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

5 Day Chart for NASDAQ:APTO

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.